Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04838431
Other study ID # AOU: 0001395/20
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date June 1, 2018
Est. completion date December 31, 2019

Study information

Verified date May 2022
Source University of Modena and Reggio Emilia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Large for gestational age infants (LGA) have increased risks of adverse short-term perinatal outcomes. This study aims to develop a multivariable prediction model for the risk of giving birth to a LGA baby, by using biochemical, biophysical, anamnestic, and clinical maternal characteristics available at first trimester. This prospective study includes all singleton pregnancies attending the first trimester aneuploidy screening at the Obstetric Unit of the University Hospital of Modena, in Northern Italy.


Description:

For each subject, blood sample is collected in fasting conditions, then centrifuged, and the serum stored at minus 80° C, for subsequent biochemical analyses. PAPP-A, PlGF and Inibin A is measured with the automated DELFIA EXPRESS system (Thermo Fisher Scientific, Perkin Elmer ®). Insulin, high density lipoproteins (HDL) and triglycerides are measured through routine laboratory methods. The mean arterial pressure (MAP) is measured with validated automated devices (Dinamap, BLTV6XX). After the women are seated and allowed to rest for 3-5 min, normal (22 to 32 cm) adult cuffs are fitted to their both arms. This is repeated two times with 1 min break in between. The MAP is calculated with the formula MAP DBP + 1/3(SBP - DBP) 21, where DBP represents diastolic blood pressure and SBP, systolic blood pressure. We calculate the final MAP as the average of all four measurements. Uterine artery Doppler studies including pulsatility index are measured through trans-abdominal ultrasound (Voluson E8 or Voluson E10) examinations. As indicated in Fetal Medicine Foundation (FMF), when carrying out Doppler studies, color flow mapping is used to identify each uterine artery along the side of the cervix and uterus at the level of the cervical internal os. Pulsed wave Doppler imaging is used with the sampling gate set at 2 mm to cover the whole vessel, and care is taken to ensure that the angle of insonation is less than 30°. When three to five similar consecutive waveforms are obtained, PI is measured. The uterine artery mPI is calculated by adding the right and left pulsatility index together, divided by two. All ultrasound and Doppler studies are carried out by a physician who had received the appropriate certificate of competence in the 11-13+6 week scans and Doppler study from the FMF. Data on pregnancy outcome are collected from the hospital maternity records or directly from women if delivered elsewhere. Medical records are reviewed by research associates to obtain anonymized data on mothers (i.e maternal demographics, BMI, age…) and their newborns (birthweight, gender, Apgar score, admission to the neonatal intensive care unit (NICU) and length of stay, neonatal morbidities, and mortality), and are organized in a password protected database.


Recruitment information / eligibility

Status Terminated
Enrollment 503
Est. completion date December 31, 2019
Est. primary completion date June 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Singleton pregnancies attending the first trimester Down syndrome screening at the University Hospital of Modena, in the North of Italy (tertiary Hospital). Exclusion Criteria: - Twin pregnancies - Pregnancies with major fetal abnormalities

Study Design


Intervention

Other:
Blood sample and ultrasound at first trimester
The blood sample and the ultrasound are part of the routine care for the aneuploidy screening at first trimester. We deepened the biochemicals and biophysical markers for predicting the risk for large for gestational age infants

Locations

Country Name City State
Italy University Hospital of Modena Modena

Sponsors (1)

Lead Sponsor Collaborator
University of Modena and Reggio Emilia

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary LGA Risk for delivering a LGA infant, by combining the birtweight, the infant gender and the gestational age at birth From 37-42 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06198881 - Association Between Labor Induction and Birth Weight in Cases of Fetal Macrosomia: The MACROMODA Cohort Study
Completed NCT03726697 - Effect of Tahneek on Hypoglycemia in Newborn Infants N/A
Not yet recruiting NCT06283277 - Fetal Clavicular Measurement to Predict Fetal Macrosomia
Completed NCT03165643 - The DNA Methylation of ARHGEF11 in Macrosomia N/A
Active, not recruiting NCT03146156 - Lifestyle Intervention in Preparation for Pregnancy (LIPP) N/A
Recruiting NCT05410080 - the Efficacy of Fetal Arterial and Venous Doppler Indices in Predicting Perinatal Outcome
Withdrawn NCT03218735 - Early Term Delivery Versus Expectant Management of the Large for Gestational Age Fetus N/A
Recruiting NCT06281301 - Improving Patient Understanding of Macrosomia N/A
Not yet recruiting NCT05197101 - To Evaluate the Efficacy and Safety of Balloon Catheter Combined With Oxytocin Induction in Nulliparous Women With Estimated Fetal Weight ≥3500g at 39-40 Weeks of Gestation N/A
Recruiting NCT06048510 - New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia. N/A
Completed NCT05760768 - The Effect of Individualized Exercise Guidance on Pregnancy Outcome N/A
Not yet recruiting NCT05510518 - Late Gestational Diabetes Mellitus Diagnosis in Obese Women
Withdrawn NCT02478554 - Antenatal Development Evaluated Prospectively N/A